Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-13
2005-09-13
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C424S001410
Reexamination Certificate
active
06943146
ABSTRACT:
The present invention relates to a method for enhancing angiogenic activity to promote neovascularization comprising administering to a subject a formulation comprising a synergistically effective amount of a TWEAK agonist and an angiogenic factor.
REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5858991 (1999-01-01), Hellerqvist et al.
patent: 6207642 (2001-03-01), Wiley
patent: 6448042 (2002-09-01), Greene et al.
patent: 6544761 (2003-04-01), Greene et al.
patent: 6727225 (2004-04-01), Wiley
patent: 6824773 (2004-11-01), Wiley
patent: 2002/0004041 (2002-01-01), Albert et al.
patent: 2002/0041876 (2002-04-01), Wiley
patent: 2002/0042368 (2002-04-01), Fanslow, III et al.
patent: 2002/0110853 (2002-08-01), Wiley
patent: 2003/0100074 (2003-05-01), Yu et al.
patent: 2003/0162712 (2003-08-01), Cerretti et al.
patent: 2003/0170228 (2003-09-01), Ashkenazi et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2003/0211096 (2003-11-01), Ashkenazi et al.
patent: 2003/0216546 (2003-11-01), Tykocinski et al.
patent: 2004/0014176 (2004-01-01), Ashkenzai et al.
patent: 2004/0018170 (2004-01-01), Shirwan
patent: 2004/0033225 (2004-02-01), Browning et al.
patent: 2004/0038349 (2004-02-01), Hilbert et al.
patent: 2004/0047854 (2004-03-01), Black et al.
patent: 2004/0091473 (2004-05-01), DuBose et al.
patent: 2005/0008636 (2005-01-01), Rennert
patent: 2005/0054568 (2005-03-01), Ling et al.
patent: WO 96/18725 (1996-06-01), None
patent: WO 98/05783 (1998-02-01), None
patent: WO 98/35061 (1998-08-01), None
patent: WO 98/55508 (1998-12-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 99/59614 (1999-11-01), None
patent: WO 99/61471 (1999-12-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 00/42073 (2000-07-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 01/53486 (2001-07-01), None
patent: WO 03/086311 (2003-10-01), None
Lynch, C. N. et al., “TWEAK Induces Angiogenesis and Proliferation of Endothelial Cells,”Journal of Biological Chemistry274(13): 8455-8459 (1999).
Jakubowski, A. et al., “TWEAK Synergizes With Basic Fibroblast Growth Factor to Induce Endothelial Cell Proliferation, Migration and Lumen Morphogenesis ,”Scandinavian Journal of Immunology51(Supplement 1): 62 (2000).
U.S. Appl. No. 09/245,198, Chicheportiche et al.
U.S. Appl. No. 10/978,203, Chicheportiche et al.
U.S. Appl. No. 10/978,131, Chicheportiche et al.
Chicheportiche et al. “Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory Pathologies.” Biochem Biophys Res Commun. Dec. 9, 2000;279(1):162-5.
Chicheportiche et al. “Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies.” Arthritis Res. 2002;4(2):162-33. Epub Nov. 9, 2001.
Chicheportiche et al. “TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis.” J Biol Chem. Dec. 19, 1997;272(51):32401-10.
Jakubowski et al. “Dual role for TWEAK in angiogenic regulation.” J Cell Sci. Jan. 15, 2002;115(Pt 2):267-74.
Nagata (1997) “Apoptosis by Death Factor” Cell 88:355-365.
Pepper MS et al. “Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis.” Exp Cell Res. Feb. 1993;204(2):356-63.
Wiley et al. (1995) “Identification and Characterization of a New Member of the TNF Family that induces Apoptosis” Immunity 3:673-682.
Ward et al., “Blocking of adhesion moleculesin vivoas anti-inflammatory therapy”, Ther. Immunol., vol. 1(3), pp. 165-171 (1994).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem, Chapter 14, pp. 435-508 (1994).
Dallman, “Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult”, Current Opinion in Immunology, vol. 7, pp. 632-638 (1995).
Krenger and Farrara, “Graft-versus-Host Disease and the Th1/Th2 Paradigm”, Immunol. Res., vol. 15, pp. 50-73 (1996).
Abbas AK et al. (eds), Chapter Fifteen, “Immunity to Microbes”,Cellular and Molecular Immunology, Philadelphia: WB Saunders Co. pp. 302-314 (1991).
Abbas AK et al. (eds), Chapter One, “General Properties of Immune Responses”, Introduction to Immunology,Cellular and Molecular Immunology, Philadelphia: WB Saunders Co. pp. 4-12 (1991).
Toogood et al., “The Immune Response Following Small Bowel Transplantation”, Transplantation, vol. 62(6), pp. 851-855 (1996).
De Wit et al., “Preferential Activation of Th2 Cells in Chronic Graft-versus-Host Reaction”, The Journal of Immunology, Col. 150(2), pp. 361-366 (1993).
Williamson et al., “IL-12 Is a Central Mediator of Acute Graft-Versus-Host Disease in Mice”, J. Immunol., pp. 689-699 (1996).
Chaplin and Fu, “Cytokine regulation of secondary lymphoid organ development”, Current Opinion in Immunology, vol. 10, pp. 288-297 (1998).
Grewal and Flavell, “The CD40 Ligand”, Immunol. Res., vol. 16, pp. 59-70 (1997).
Mackay and Browning, “Turning off follicular dendritic cells”, Nature, vol. 395, pp. 26-27 (1998).
Flynn et al., “CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor Blr-1”, J. Exp. Med., vol. 188, pp. 297-304 (1998).
Lynch et al., “Tweak Induces Proliferation in Endothelial Cells and Substitutes For EGF and Hydrocortisone in Culture”, Interferon Cytokine Res., vol. 18, A-46 (1998).
Marsters et al., “Identification of a ligand for the death-domain-containing receptor Apo3”, Current Biology, vol. 8, pp. 525-528 (1998).
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation”, Science, vol. 281, pp. 1305-1308 (1998).
Lenschow et al., “Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse”, J. Exp. Med., vol. 181, pp. 1145-1155 (1995).
Durie et al., “Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease”, J. Clin. Invest., vol. 94, pp. 1333-1338 (1994).
Grewal and Flavell, “The Role of CD40 Ligand in Costimulation and T-Cell Activation”, Immunol. Rev., vol. 153, pp. 85-106 (1996).
Mohan et al., “Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis1”, J. Immunol., vol. 154, pp. 1470-1480 (1995).
Kalled et al., “Anti-CD40 Ligand Antibody Treatment of SNF1Mice with Established Nephritis: Preservation of Kidney Function”, J. Immunol., vol. 160, pp. 2158-2165 (1998).
Bach-Elias et al., “Presence of autoantibodies against small nuclear ribonucleoprotein epitopes in Chagas' patients' sera”, Parasitol. Res., vol. 84, pp. 196-799 (1998).
Tibbetts et al., “Cardiac Antigen-Specific Autoantibody Production is Associated with Cardiomyopathy inTypansomacruzi-Infected Mice1”, J. Immunol., vol. 152, pp. 1493-1499 (1994).
Kirk et al., “CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 8789-8794 (1997).
Kaplan et al., “Th2 Lymphocytes Kill Antigen Presenting Macrophages Through a TWEAK Dependant Pathway”, J. of Investigate Medicine, vol. 46:287A (1998).
Meighan-Mantha et al., “The Mitogen-inducible Fn14 Gene Encodes a Type I Transmembrane Protein that Modulates Fibroblast Adhesion and Migration” J. Biol. Chem., 274: 33166-33176 (Nov. 1999).
Cassiano et al., “Molecular Cloning of a Novel Receptor for TWEAK”, Scand. J. Immunol. 51 (Supp. 1) 1-111.
Browning et al., “Characterization of Surface Lymphotoxin Forms” J. Immunol, 1
Burkly Linda
Jakubowski Aniela
Biogen Idec MA Inc.
Fish & Richardson P.C.
Wax Robert A.
LandOfFree
Method for promoting neovascularization does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for promoting neovascularization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for promoting neovascularization will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3385122